Full Press Release Details
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022.
IMMP
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
Key Takeaway: Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
Price reaction · baseline $2.8 (2022-05-26 close) · hit after-hours · 2 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
+4.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)